These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16688193)

  • 1. Diarrhea induced by high doses of nicotinamide in dialysis patients.
    Delanaye P; Weekers L; Krzesinski JM
    Kidney Int; 2006 May; 69(10):1914. PubMed ID: 16688193
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients.
    Cheng SC; Young DO; Huang Y; Delmez JA; Coyne DW
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1131-8. PubMed ID: 18385391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients.
    Iwasaki Y; Takami H; Tani M; Yamaguchi Y; Goto H; Goto Y; Goto Y; Shigematsu T
    Ther Apher Dial; 2005 Aug; 9(4):347-51. PubMed ID: 16076380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sevelamer worsens metabolic acidosis in hemodialysis patients.
    De Santo NG; Frangiosa A; Anastasio P; Marino A; Correale G; Perna A; Di Stazio E; Stellato D; Santoro D; Di Meglio E; Iacono G; Ciacci C; Savica V; Cirillo M
    J Nephrol; 2006; 19 Suppl 9():S108-14. PubMed ID: 16736432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan.
    Koiwa F; Onoda N; Kato H; Tokumoto A; Okada T; Fukagawa M; Shigematsu T;
    Ther Apher Dial; 2005 Aug; 9(4):340-6. PubMed ID: 16076379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotinamide: An Update and Review of Safety & Differences from Niacin.
    Huber R; Wong A
    Skin Therapy Lett; 2020 Nov; 25(5):7-11. PubMed ID: 33196157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombocytopenia induced by nicotinamide in hemodialysis patients.
    Rottembourg JB; Launay-Vacher V; Massard J
    Kidney Int; 2005 Dec; 68(6):2911-2. PubMed ID: 16316377
    [No Abstract]   [Full Text] [Related]  

  • 9. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer.
    Russo D; Miranda I; Ruocco C; Battaglia Y; Buonanno E; Manzi S; Russo L; Scafarto A; Andreucci VE
    Kidney Int; 2007 Nov; 72(10):1255-61. PubMed ID: 17805238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.
    Kakuta T; Tanaka R; Hyodo T; Suzuki H; Kanai G; Nagaoka M; Takahashi H; Hirawa N; Oogushi Y; Miyata T; Kobayashi H; Fukagawa M; Saito A
    Am J Kidney Dis; 2011 Mar; 57(3):422-31. PubMed ID: 21239096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sevelamer is cost-saving vs. calcium carbonate in non-dialysis-dependent CKD patients in italy: a patient-level cost-effectiveness analysis of the INDEPENDENT study.
    Ruggeri M; Cipriani F; Bellasi A; Russo D; Di Iorio B
    Blood Purif; 2014; 37(4):316-24. PubMed ID: 25171148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial.
    Di Iorio B; Molony D; Bell C; Cucciniello E; Bellizzi V; Russo D; Bellasi A;
    Am J Kidney Dis; 2013 Oct; 62(4):771-8. PubMed ID: 23684755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial.
    Shahbazian H; Zafar Mohtashami A; Ghorbani A; Abbaspour MR; Belladi Musavi SS; Hayati F; Lashkarara GR
    Nefrologia; 2011; 31(1):58-65. PubMed ID: 21270914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival in end stage renal disease: calcium carbonate vs. sevelamer.
    Borzecki AM; Lee A; Wang SW; Brenner L; Kazis LE
    J Clin Pharm Ther; 2007 Dec; 32(6):617-24. PubMed ID: 18021340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of nicotinamide: treatment of skin diseases and potential side effects.
    Rolfe HM
    J Cosmet Dermatol; 2014 Dec; 13(4):324-8. PubMed ID: 25399625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients.
    Lin HH; Liou HH; Wu MS; Lin CY; Huang CC
    Nephrology (Carlton); 2014 Nov; 19(11):672-8. PubMed ID: 25113414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis.
    Chennasamudram SP; Noor T; Vasylyeva TL
    J Ren Care; 2013 Jun; 39(2):82-9. PubMed ID: 23574727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis—sevelamer hydrochloride, calcium carbonate, and bixalomer.
    Sanai T; Tada H; Ono T; Fukumitsu T
    Hemodial Int; 2015 Jan; 19(1):54-9. PubMed ID: 24980286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Either calcium carbonate or sevelamer decreases urinary oxalate excretion in chronic renal failure patients].
    Caravaca F; Ruiz AB; Escola JM; Hernández Gallego R; Cerezo I; Fernández N; Barroso S; Martín MV
    Nefrologia; 2007; 27(4):466-71. PubMed ID: 17944584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis].
    Hashimoto N; Miyata M; Sato N; Mochizuki T; Koike T
    Clin Calcium; 2005 Sep; 15 Suppl 1():30-4; discussion 34. PubMed ID: 16272626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.